We are committed to developing immunotherapy treatments to improve the lives of cancer patients across the globe.
Our pipeline is focused on dual-acting immunotherapies that incorporate a T-cell activator and a T-cell co-stimulator into a single injection. Through this, we hope to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologic products.
Combination Therapies Designed to Activate CD8+ T-cells to Fight Cancer
|Combination Therapies||Indication||Pre-clinical||Phase 1||Phase 2||Phase 3||Approved||Comments|
|HS-110 (viagenpumatucel-L)||NSCLC||ImPACT® activation technology in combination with nivolumab and other checkpoint inhibitors TBA|
|HS-120||NSCLC||ComPACT™ activation technology in combination with checkpoint inhibitors TBA|
|PTX-35||TBA||Humanized monoclonal antibody, functional agonist of human TNFRSF25|
|PTX-15||TBA||TL1A-lg fusion protein, functional agonist of human TNFRSF25|
HS-110 Phase 2 (DURGA) Clinical Trial
HS-110 is in Phase 2 study for the potential treatment of non-small cell lung cancer (NSCLC), in combination with Bristol-Myers Squibb’s checkpoint inhibitor, nivolumab (Opdivo®). Our therapeutic drug is designed to secrete a wide range of lung cancer-associated antigens bound to gp96 proteins, while activating a broad, T-cell mediated immune response against cancer.